THROMBOLYTIC SCIENCE INTERNATIONAL

thrombolytic-science-international-logo

Thrombolytic Science is focused on developing a proprietary product, M5, a mutant of pro-urokinase (proUK). M5 is a thrombolytic that follows a different paradigm than tPA, has superior efficacy and is accompanied by little bleeding risk.

#SimilarOrganizations #People #Website #More

THROMBOLYTIC SCIENCE INTERNATIONAL

Social Links:

Industry:
Biotechnology Therapeutics

Founded:
2004-01-01

Address:
Cambridge, Massachusetts, United States

Country:
United States

Website Url:
http://www.tsillc.net

Total Employee:
1+

Status:
Active

Contact:
617-661-1103

Total Funding:
7.5 M USD

Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Content Delivery Network SSL By Default HSTS Microsoft Exchange Online Google Cloud Microsoft Azure DNS


Similar Organizations

bilayer-therapeutics-logo

Bilayer Therapeutics

Bilayer Therapeutics is a biotech company that develops a first-in-class therapeutic for constipation and other diseases of the colon.

galenea-logo

Galenea

Galenea is engaged in developing therapeutics for central nervous system diseases.

Current Employees Featured

alexis-c-wallace_image

Alexis C. Wallace
Alexis C. Wallace President and Chief Executive Officer, Director and Co-founder @ Thrombolytic Science International
President and Chief Executive Officer, Director and Co-founder
2008-01-01

not_available_image

Victor Gurewich
Victor Gurewich Chief Scientific Officer @ Thrombolytic Science International
Chief Scientific Officer

Founder


alexis-c-wallace_image

Alexis C. Wallace

not_available_image

Victor Gurewich

Official Site Inspections

http://www.tsillc.net

  • Host name: unalocated.63.wixsite.com
  • IP address: 185.230.63.171
  • Location: Ashburn United States
  • Latitude: 39.018
  • Longitude: -77.539
  • Metro Code: 511
  • Timezone: America/New_York
  • Postal: 20147

Loading ...

More informations about "Thrombolytic Science International"

Cardiovascular Stroke Clinical Trials | TSI, LLC | United โ€ฆ

TSI is to transform the treatment of thrombotic diseases like ischemic stroke, by taking its drug to the patient, instead of taking the patient to the drug, dramatically improving patient access to a life-saving solution. Only an intravenous Rx can โ€ฆSee details»

Thrombolytic Science International - Crunchbase

Thrombolytic Science is focused on developing a proprietary product, M5, a mutant of pro-urokinase (proUK). M5 is a thrombolytic that follows a different paradigm than tPA, has โ€ฆSee details»

Thrombolytic Science International - Wikipedia

Thrombolytic Science, LLC (TSI) is a private, clinical stage biopharmaceutical company that was founded in 2006 based on the research of Harvard scientist Victor Gurewich into the potential use of prourokinase to break up blood clots. Gurewich co-founded the company and the founding CEO is business person Alexis Wallace. See details»

Thrombolytic Science, LLC Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Thrombolytic Science, LLC of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»

Thrombolytic Science Company Profile 2024: Valuation, Funding ...

Thrombolytic Science General Information Description. Developer of biotherapeutics for heart attack and stroke treatment. The company develops clot-dissolving therapy for stroke and โ€ฆSee details»

Thrombolytic Science - Company Profile - Tracxn

Oct 20, 2024 Thrombolytic Science - Developer of mutant prounokinase to treat thrombotic diseases. Raised a total funding of $7.5M over 1 round. Founded by Alexis Wallace and Victor โ€ฆSee details»

Thrombolytic Science International - Products, Competitors, โ€ฆ

Tsillc.net. Overview & Products; Financials; People; Founded Year 2006. Stage Unattributed | Alive. Total Raised $7.5M. Last Raised $7.5M | 13 yrs ago. About Thrombolytic Science โ€ฆSee details»

Thrombolytic Science International - VentureRadar

"Thrombolytic Science (TSI) is a private, clinical stage, vascular medicine and biotech company. We are leading the clinical development of fibrinolysis without bleeding to change the โ€ฆSee details»

Thrombolytic Science - Craft

Thrombolytic Science has 5 employees at their 1 location and $7.5 m in total funding,. See insights on Thrombolytic Science including office locations, competitors, revenue, financials, โ€ฆSee details»

Thrombolytic Science International LLC - Drug pipelines, Patents ...

Explore Thrombolytic Science International LLC with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 1 news, Drug:tPA/HisproUK(Thrombolytic Science โ€ฆSee details»

Thrombolytic Science - Overview, News & Similar companies

View Thrombolytic Science (www.tsillc.net) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as employees by title and โ€ฆSee details»

Thrombolytic Science - LinkedIn

Thrombolytic Science | 152 followers on LinkedIn. Re-establishing blood flow faster, without bleeding, for stroke and heart attack patients. | TSI is a privately-held vascular medicine and ...See details»

Free WHOIS tsillc.net Domain Name Lookup | IP2WHOIS.com

IP2WHOIS is a free WHOIS Lookup (Domain lookup) tool that helps user to check WHOIS information for a particular domain, such as domain assigned owner contact information, โ€ฆSee details»

Thrombolytic Science Announces the Appointment of Michael โ€ฆ

Nov 15, 2017 For more information, please visit www.tsillc.net. Alexis C. Wallace Thrombolytic Science, LLC +1 617-661-1103 email us here. Share on Facebook · Twitter · LinkedIn. โ€ฆSee details»

TSI Completes Phase 1 Clinical Trial of Novel Clot ... - PR Newswire

Sep 18, 2017 For more information, please visit tsillc.net. Corporate Contact Alexis Wallace, M.Sc.Eng., MBA President & CEO T: 617-661-1103 [email protected] SOURCE Thrombolytic โ€ฆSee details»

Thrombolytic Science, LLC to Collaborate With National Institutes โ€ฆ

CAMBRIDGE, Mass., June 1, 2015 /PRNewswire/ -- Thrombolytic Science, LLC (TSI) announced today that is has entered into an agreement with the National Institutes of Health (NIH). Under โ€ฆSee details»

TSI Initiates Phase 1 Study of New-Generation Thrombolytic, TS01

CAMBRIDGE, Mass., Oct. 2, 2012 /PRNewswire/ -- Thrombolytic Science International (TSI) today announced the initiation of a Phase 1 study of TS01, a new-generation clot-dissolving โ€ฆSee details»

TSI Completes Phase I Clinical Trial of Novel Clot ... - BioSpace

CAMBRIDGE, Mass., Sept. 18, 2017 /PRNewswire/ -- Thrombolytic Science, LLC (TSI), a clinical stage vascular health and biotechnology company, today announced the completion of a โ€ฆSee details»

Understanding Accreditation: What Students Need to Know

5 days ago According to the International Laboratory Accreditation Cooperation (ILAC), an international organization for accreditation bodies, accreditation is defined as: โ€œthe โ€ฆSee details»

Login | Mobis - microfinance.mobisapp.net

Enter the hyphen-separated version of your organization's name. Please ask your manager if you're unsure of your organization's login. Choose Organization ...See details»

linkstock.net © 2022. All rights reserved